Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
27 Jun 2016 04:35 PM
RNS
Price Monitoring Extension
20 Jun 2016 07:00 AM
RNS
Appointment of Joint Broker
09 Jun 2016 05:56 PM
RNS
Holding(s) in Company
08 Jun 2016 07:00 AM
RNS
Symposium with Lupuzors Inventor Prof. S Muller
07 Jun 2016 07:00 AM
RNS
European Patients Commence Dosing in Lupuzor
02 Jun 2016 05:26 PM
RNS
Director/PDMR Shareholding
31 May 2016 10:38 AM
RNS
Holding(s) in Company
26 May 2016 02:00 PM
RNS
Result of AGM
25 May 2016 07:00 AM
RNS
Holding(s) in Company
04 May 2016 07:01 AM
RNS
Annual Financial Report & Notice of AGM
04 May 2016 07:00 AM
RNS
Final Results
26 Apr 2016 07:00 AM
RNS
Notice of Results
22 Apr 2016 09:50 AM
RNS
Holding(s) in Company
09 Mar 2016 07:00 AM
RNS
First European Site Opens - Patient Recruitment
08 Mar 2016 11:10 AM
RNS
Holding(s) in Company
07 Mar 2016 03:31 PM
RNS
Holding(s) in Company
01 Mar 2016 07:00 AM
RNS
EIS and VCT Qualifying Status and Issue of Equity
29 Feb 2016 08:02 AM
RNS
Holding(s) in Company
24 Feb 2016 12:35 PM
RNS
Issue of Equity
22 Feb 2016 01:39 PM
RNS
Result of GM
15 Feb 2016 07:00 AM
RNS
US PATIENTS COMMENCE DOSING IN PHASE III STUDY
05 Feb 2016 12:22 PM
RNS
Placing and Subscription Raises £8.3 million
05 Feb 2016 07:00 AM
RNS
Proposed Placing and Subscription
21 Jan 2016 05:33 PM
RNS
Holding(s) in Company
15 Dec 2015 07:00 AM
RNS
ImmuPharma & Simbec-Orion - Investigators Meeting
07 Dec 2015 07:00 AM
RNS
Update on the progress of Lupuzor
30 Nov 2015 11:55 AM
RNS
Holding(s) in Company
04 Nov 2015 08:26 AM
RNS
Lupuzor Phase III Pivotal Trial Update
04 Nov 2015 07:00 AM
RNS
Lupuzor Phase III Pivotal Trial Update
23 Oct 2015 07:00 AM
RNS
Directorate Change
30 Sep 2015 07:05 AM
RNS
Directorate Change
30 Sep 2015 07:00 AM
RNS
Interim Results
29 Jul 2015 07:00 AM
RNS
Richard Warr
27 Jul 2015 07:00 AM
RNS
TERM SHEET SIGNED $14 MILLION FUNDING FOR LUPUZOR
25 Jun 2015 07:00 AM
RNS
Lupuzor's Founder Dr Slyviane Muller Awarded Medal
29 May 2015 12:50 PM
RNS
Result of AGM
06 May 2015 03:44 PM
RNS
Annual Report & Accounts
06 May 2015 07:02 AM
RNS
Interim Board Change
30 Apr 2015 07:05 AM
RNS
Directorate Change
30 Apr 2015 07:00 AM
RNS
Preliminary Results
11 Feb 2015 12:02 PM
RNS
CANCER UPDATE: IPP-204106
27 Jan 2015 07:00 AM
RNS
Enterprise Investment Scheme Status
22 Jan 2015 07:00 AM
RNS
Collaboration Agreement with Simbec-Orion
30 Oct 2014 11:10 AM
RNS
Holding(s) in Company
28 Oct 2014 07:00 AM
RNS
Holding(s) in Company
21 Oct 2014 07:00 AM
RNS
Additional Listing - Conditional Placing
20 Oct 2014 07:00 AM
RNS
ImmuPharma awarded EUR400,000 Grant
30 Sep 2014 07:05 AM
RNS
Half Yearly Report
30 Sep 2014 07:00 AM
RNS
LupuzorT Gears Up To Start Pivotal Phase III trial
27 Jun 2014 01:11 PM
RNS
Result of AGM

mmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

UK 100

Latest directors dealings